查看购物车
  • Traditional Chinese
  • English
  • Japanese
医疗事务的评价(美国)- 慢性特发性荨麻疹
市场调查报告书
商品编码
1745091

医疗事务的评价(美国)- 慢性特发性荨麻疹

Medical Affairs Reputations (US) - Chronic Spontaneous Urticaria
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

最近一项针对美国过敏症专家的调查显示，几家大型慢性特发性荨麻疹医疗事务团队在几个关键领域仍有很长的路要走。我们揭示了医生们认为自己做得好的方面、他们希望改进的方面以及不满意的原因。在本报告中，我们揭示了医疗事务如何满足治疗慢性特发性荨麻疹医师的高期望。我们比较了几家领先的慢性特发性荨麻疹公司医疗事务团队的当前表现。

关键问题

  • 1.医师与医疗事务团队的互动频率为何？这种频率是在增加还是在减少？
  • 2.医师目前如何使用医疗事务团队提供的服务？
  • 3.医疗事务支援的哪些面向对医师来说最重要？他们对所提供的支援有多满意？
  • 4.医师希望与医疗事务团队进行哪种类型的互动？他们希望这种互动的频率是多少？
  • 5.医疗事务团队如何更能满足医师的需求？
  • 6.医疗事务团队在特定品牌的表现是低于还是高于预期？
  • 7.未来您可以如何改善医疗事务服务，以便更好地满足医师的需求？
  • 8.竞争对手的医疗事务团队在哪些方面最弱，哪些方面最强？

领导品牌

  • zorea(Omalizumab)
  • deyupikusento(deyupirumabu)
  • remiburuchinibu
  • baruzoruborimabu

调查手法

FirstView 报告是基于透过 LiMATM 选定的医生进行的定量调查得出。 LiMATM 是全球最大的医生名录，拥有超过 300 万名已确认的医生。医生。每位医生均根据严格的筛选标准精心挑选，以确保收集到的见解具有相关性、可靠性，并反映顶尖医疗专业人士的真实声音和经验。研究结果以易于理解的图表形式呈现，方便您快速消化和分析数据。凭藉 LiMATM 的广泛覆盖范围和精准度，FirstView Reports 提供无与伦比的数据驱动洞察，指导您的策略规划，并帮助您在快速发展的医疗保健领域保持领先地位。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助您掌握新兴趋势并有效解决复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告可提供您所需的准确性和可靠性。独家独家访谈和数据，以及持续的市场监测，让您全面洞察市场动态。我们的报告涵盖 40 多个活跃疾病领域，汇集医生情报（包括 KOL 洞察和定量医生调查），以及行业专家对医疗事务、数位医疗、销售与行销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。

简介目录

According to this latest survey of US allergists, the performance of chronic spontaneous urticaria medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating chronic spontaneous urticaria. It compares the current performance of medical affairs teams for several leading treatments for chronic spontaneous urticaria from various companies.

Key Questions Answered:

  • 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
  • 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • 5. How successful are Medical Affairs teams at meeting physician needs?
  • 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Xolair (omalizumab)
  • Dupixent (dupilumab)
  • remibrutinib
  • barzolvolimab

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.